RMC-6236

Dana-Farber Cancer Institute researchers are presenting multiple groundbreaking studies on head and neck, breast, and lung cancers at the 2025 AACR Annual Meeting in Chicago from April 25-30.

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.

A groundbreaking experimental drug, daraxonrasib by Revolution Medicines, demonstrates encouraging results in treating late-stage pancreatic cancer patients, offering new hope in a traditionally difficult-to-treat disease.

Tango Therapeutics' lead candidate TNG462 has been granted Orphan Drug Designation by the FDA for pancreatic cancer treatment, providing seven years of market exclusivity upon approval.

Phase 1 trial of daraxonrasib (RMC-6236) in RAS-mutant pancreatic ductal adenocarcinoma (PDAC) demonstrates encouraging early results.